Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 26
Filtrar
1.
Oncogenesis ; 3: e91, 2014 Mar 17.
Artigo em Inglês | MEDLINE | ID: mdl-24637491

RESUMO

Recent studies have demonstrated a relationship between the expression of stem cell-associated genes and relapses in glioblastoma (GBM), suggesting a key role for tumor stem cells in this process. Although there is increasing interest in this field, glioma stem cells (GSCs) are still poorly characterized, their 'stemness' state and factors maintaining these properties remain largely unknown. We performed an expression profiling analysis of pluripotency in gliomaspheres derived from 11 patients. Comparative analysis between GSCs and H1 and H9 human embryonic stem cells as well as H9-derived neural stem cells indicates major variations in gene expression of pluripotency factors Nanog and OCT4, but a stable pattern for SOX2 suggesting its important function in maintaining pluripotency in GSCs. Our results also showed that all GSC lines have the capacity to commit to neural differentiation and express mesenchymal or endothelial differentiation markers. In addition, hierarchical clustering analysis revealed two groups of GSCs reflecting their heterogeneity and identified COL1A1 and IFITM1 as the most discriminating genes. Similar patterns have been observed in tumors from which gliomaspheres have been established. To determine whether this heterogeneity could be clinically relevant, the expression of both genes was further analyzed in an independent cohort of 30 patients with GBM and revealed strong correlation with overall survival. In vitro silencing of COL1A1 and IFTM1 confirmed the effect of these mesenchymal-associated genes on cell invasion and gliomasphere initiation. Our results indicate that COL1A1 and IFITM1 genes could be considered for use in stratifying patients with GBM into subgroups for risk of recurrence at diagnosis, as well as for prognostic and therapeutic evolution.

3.
Platelets ; 20(7): 471-7, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19852685

RESUMO

Despite its widespread use, there are many concerns about the efficacy of aspirin in the secondary prevention of cardiovascular events after stroke, leading to the concept of aspirin non-response (ANR). Although the mechanisms of ANR remain uncertain, it is expected to be due to a combination of clinical, biological and genetic characteristics affecting platelet function. In this study, we investigated whether clinical and/or biological factors such as hypertension and platelet response to ADP could contribute to the ANR. As a secondary objective, we determine whether ANR and collagen/ADP closure time (CADP-CT) could be related to platelet glycoprotein single nucleotide polymorphisms (SNPs). One hundred patients on aspirin (160 mg/day) were enrolled. ANR was measured with a platelet function analyzer (PFA-100); genotyping of four SNPs (GP IIIa, GP Ia, P2Y12 and GP VI) was performed using a tetra-primer amplification refractory mutation system. Using a collagen/epinephrine-coated cartridge on the PFA-100, the prevalence of ANR was 15% (n = 15). In the ANR group, (i) CADP-CT was significantly shorter and (ii) hypertension was an independent clinical predictive factor of ANR (OR = 4.25; 95%CI: 1.06-17.11). No clear relation was found between CADT-CT and platelet gene polymorphism as well as ANR status and SNPs. In conclusion our study confirms the independent relationship between hypertension, platelet hypersensitivity to ADP and aspirin (160 mg/day) non-response. The differential sensitivity to aspirin may have potential clinical implications, where adaptation of antiplatelet therapy is necessary according to a patient's clinical and genetic characteristics.


Assuntos
Difosfato de Adenosina/uso terapêutico , Aspirina/uso terapêutico , Hipertensão/prevenção & controle , Inibidores da Agregação Plaquetária/uso terapêutico , Acidente Vascular Cerebral/tratamento farmacológico , Idoso , Plaquetas/fisiologia , Feminino , Humanos , Hipertensão/sangue , Hipertensão/genética , Masculino , Pessoa de Meia-Idade , Agregação Plaquetária/efeitos dos fármacos , Agregação Plaquetária/genética , Polimorfismo Genético , Polimorfismo de Nucleotídeo Único , Estudos Prospectivos , Acidente Vascular Cerebral/sangue , Acidente Vascular Cerebral/genética , Acidente Vascular Cerebral/prevenção & controle
5.
Leuk Lymphoma ; 42(5): 933-44, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11697648

RESUMO

Persistence of BCR-ABL rearrangements was demonstrated by D-FISH technique in chronic myeloid leukemia (CML) patients in complete cytogenetic response (CCR) after allogeneic bone marrow transplantation (BMT) or interferon-alpha therapy (IFN-alpha). Samples from bone marrow aspirate or peripheral blood or both were analyzed by conventional cytogenetics, Southern blot, fluorescent interphase in situ hybridization (FISH), and quantitative reverse transcription polymerase chain reaction (Q-RT-PCR). In all patients, FISH detected 1% to 12% nuclei with a BCR-ABL fusion gene, whereas Q-RT-PCR were negative or weakly positive. Based on these results, we hypothesize that the BCR-ABL genomic rearrangement remains unexpressed in a small percentage of cells whatever the treatment (IFN-alpha or BMT), and this in spite of the negativity of the RT-PCR-based classical molecular remission criterion. These data corroborate those obtained by other investigators and point to the need for follow-up of CML patients in CCR over an extensive period, at the DNA level to evaluate the residual disease and at the RNA level (Q-RT-PCR) to estimate the risk of relapse and guide the therapeutic decision. Experimental models suggesting the persistence of positive BCR-ABL cells are discussed and tentative explanations of tumor "dormancy" are proposed.


Assuntos
Proteínas de Fusão bcr-abl/genética , Rearranjo Gênico , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Cromossomos Humanos Par 22 , Cromossomos Humanos Par 9 , Análise Citogenética , Inativação Gênica , Humanos , Leucemia Mielogênica Crônica BCR-ABL Positiva/diagnóstico , Neoplasia Residual/diagnóstico , Neoplasia Residual/genética , Translocação Genética
7.
Hum Mutat ; 16(2): 143-56, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-10923036

RESUMO

We have collated the results of cystic fibrosis (CF) mutation analysis conducted in 19 laboratories in France. We have analyzed 7, 420 CF alleles, demonstrating a total of 310 different mutations including 24 not reported previously, accounting for 93.56% of CF genes. The most common were F508del (67.18%; range 61-80), G542X (2.86%; range 1-6.7%), N1303K (2.10%; range 0.75-4.6%), and 1717-1G>A (1.31%; range 0-2.8%). Only 11 mutations had relative frequencies >0. 4%, 140 mutations were found on a small number of CF alleles (from 29 to two), and 154 were unique. These data show a clear geographical and/or ethnic variation in the distribution of the most common CF mutations. This spectrum of CF mutations, the largest ever reported in one country, has generated 481 different genotypes. We also investigated a cohort of 800 French men with congenital bilateral absence of the vas deferens (CBAVD) and identified a total of 137 different CFTR mutations. Screening for the most common CF defects in addition to assessment for IVS8-5T allowed us to detect two mutations in 47.63% and one in 24.63% of CBAVD patients. In a subset of 327 CBAVD men who were more extensively investigated through the scanning of coding/flanking sequences, 516 of 654 (78. 90%) alleles were identified, with 15.90% and 70.95% of patients carrying one or two mutations, respectively, and only 13.15% without any detectable CFTR abnormality. The distribution of genotypes, classified according to the expected effect of their mutations on CFTR protein, clearly differed between both populations. CF patients had two severe mutations (87.77%) or one severe and one mild/variable mutation (11.33%), whereas CBAVD men had either a severe and a mild/variable (87.89%) or two mild/variable (11.57%) mutations.


Assuntos
Regulador de Condutância Transmembrana em Fibrose Cística/genética , Fibrose Cística/epidemiologia , Fibrose Cística/genética , Mutação/genética , Ducto Deferente/anormalidades , Adulto , Alelos , Deleção Cromossômica , Mutação da Fase de Leitura/genética , França/epidemiologia , Frequência do Gene , Genótipo , Humanos , Infertilidade Masculina/epidemiologia , Infertilidade Masculina/genética , Masculino , Pessoa de Meia-Idade , Mutagênese Insercional/genética , Mutação de Sentido Incorreto/genética , Polimorfismo Genético/genética
8.
Blood ; 95(2): 404-8, 2000 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-10627442

RESUMO

In recent years, the prognosis of chronic myeloid leukemia (CML) has been greatly improved either with interferon-alpha (IFN-alpha) therapy or allogeneic bone marrow transplantation (BMT). In the present study, minimal residual disease was evaluated in 21 patients in complete cytogenetic response (CCR) after such treatments. Samples from bone marrow aspirates or peripheral blood or both were analyzed by conventional cytogenetics, Southern blot, interphase fluorescent in situ hybridization (FISH), and quantitative reverse transcription-polymerase chain reaction (Q-RT-PCR). In all patients, FISH detected 1% to 12% nuclei with a BCR-ABL fusion gene, whereas Q-RT-PCR experiments were negative or weakly positive. Based on these results, we hypothesize that the BCR-ABL genomic rearrangement persists unexpressed in nonproliferating cells whatever the treatment (IFN-alpha or BMT). These data point to the need for follow-up of CML patients in CCR over an extensive period at the DNA level (FISH) to evaluate the residual disease and at the RNA level (Q-RT-PCR) to estimate the risk of relapse. (Blood. 2000;95:404-408)


Assuntos
Antineoplásicos/uso terapêutico , Transplante de Medula Óssea , Proteínas de Fusão bcr-abl/genética , Rearranjo Gênico , Interferon-alfa/uso terapêutico , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia , Adulto , Idoso , Southern Blotting , Cromossomos Humanos Par 22 , Cromossomos Humanos Par 9 , Intervalo Livre de Doença , Feminino , Seguimentos , Humanos , Terapia de Imunossupressão , Hibridização in Situ Fluorescente , Cariotipagem , Masculino , Pessoa de Meia-Idade , Fatores de Tempo , Translocação Genética
9.
Biochem Biophys Res Commun ; 257(2): 577-83, 1999 Apr 13.
Artigo em Inglês | MEDLINE | ID: mdl-10198254

RESUMO

We report the cloning of a cDNA encoding human syntaxin 8 (STX8), using the regulator (R) domain of the cystic fibrosis transmembrane conductance regulator (CFTR) as a bait to screen a human fetal lung cDNA library by the yeast two-hybrid system. This gene was found broadly transcribed and its mRNA size is about 1.3 kb. The STX8 gene maps to chromosomal band 17p12 and it encodes a 236-amino-acid protein. Syntaxin 8 contains in its C-terminal half a coiled-coil domain found highly conserved in the t-SNARE (SNAP receptor on target membrane) superfamily of proteins, which are involved in vesicular trafficking and docking. In syntaxin 8, a C-terminal hydrophobic domain may constitute a transmembrane anchor. It was recently shown that CFTR-mediated chloride currents can be regulated by syntaxin 1A, a t-SNARE family member, through direct protein-protein interaction. This raises the possibility that syntaxin 8 may also be involved in such regulations.


Assuntos
Cromossomos Humanos Par 17/genética , Expressão Gênica , Proteínas de Membrana/genética , Proteínas de Transporte Vesicular , Sequência de Aminoácidos , Animais , Sequência de Bases , Northern Blotting , Mapeamento Cromossômico , Clonagem Molecular , Sequência Conservada , Regulador de Condutância Transmembrana em Fibrose Cística/genética , Regulador de Condutância Transmembrana em Fibrose Cística/metabolismo , Etiquetas de Sequências Expressas , Humanos , Pulmão/embriologia , Pulmão/metabolismo , Proteínas de Membrana/química , Proteínas de Membrana/metabolismo , Dados de Sequência Molecular , Fases de Leitura Aberta/genética , Ligação Proteica , Estrutura Secundária de Proteína , Proteínas Qa-SNARE , RNA Mensageiro/análise , RNA Mensageiro/genética , Proteínas SNARE , Homologia de Sequência de Aminoácidos , Sintaxina 1 , Leveduras/genética , Leveduras/metabolismo
11.
Leukemia ; 12(7): 1076-80, 1998 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-9665193

RESUMO

Cytogenetic, interphase fluorescent in situ hybridization (FISH) and RT-PCR methods were used to study minimal residual disease in peripheral blood stem cells collected for autografting in three chronic myeloid leukemia (CML) patients in sustained complete cytogenetic remission after treatment with interferon alpha (IFNalpha). Karyotypic analysis failed to reveal Ph-positive metaphases. FISH detected 9-16% nuclei with a BCR-ABL fusion gene, contrasting with RT-PCR, performed in two cases, which was negative in one case and weakly positive in the other. RT-PCR was also subsequently weakly positive in the third patient. This discrepancy suggests that the BCR-ABL genomic rearrangement persists unexpressed in quiescent cells. These preliminary results, which need to be confirmed in larger series, suggest that monitoring residual disease in CML should be performed both at DNA and RNA levels. Moreover, autografting following IFNalpha therapy should be considered with caution because of the persistence of the BCR-ABL genomic rearrangement in a sizeable proportion of the cells.


Assuntos
Antineoplásicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Proteínas de Fusão bcr-abl/genética , Interferon-alfa/uso terapêutico , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia , Adulto , Antineoplásicos/administração & dosagem , Fusão Gênica Artificial , Feminino , Rearranjo Gênico , Humanos , Hidroxiureia/administração & dosagem , Hibridização in Situ Fluorescente , Interferon-alfa/administração & dosagem , Masculino , Pessoa de Meia-Idade , Cromossomo Filadélfia , Reação em Cadeia da Polimerase , Indução de Remissão
12.
Leukemia ; 12(3): 326-32, 1998 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-9529126

RESUMO

The Bcr-Abl fusion protein plays a crucial role in the initiation and maintenance of chronic myelogenous leukemia (CML). However, additional events are necessary for the transition from the chronic phase to the terminal phase of the disease. To identify genes involved in the disease progression, we constructed a subtractive library from enriched K562 cell mRNA. We obtained 1084 cDNA clones. After a specific hybridization of these clones with a cDNA probe from either chronic phase or K562 cells, 43 clones which present a differential hybridization level have been selected. Among them, several clones corresponded to ribosomal protein genes showing an increased transcription level during the blast crisis. We observed variations in the expression of a cellular adhesion molecule, a laminin-binding protein. An increased transcription level of the MAZ gene has been shown in the terminal phase of the disease. This gene encodes a protein that regulates the transcription of myc.


Assuntos
Regulação Neoplásica da Expressão Gênica , Leucemia Mielogênica Crônica BCR-ABL Positiva/metabolismo , Transcrição Gênica , Crise Blástica , Proteínas de Transporte/biossíntese , Moléculas de Adesão Celular/biossíntese , Primers do DNA , Proteínas de Ligação a DNA , Progressão da Doença , Biblioteca Gênica , Humanos , Laminina/metabolismo , Leucemia Mielogênica Crônica BCR-ABL Positiva/sangue , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Contagem de Leucócitos , Reação em Cadeia da Polimerase , Proteínas Proto-Oncogênicas c-myc/biossíntese , RNA Mensageiro/biossíntese , Proteínas Ribossômicas/biossíntese , Fatores de Transcrição/biossíntese , Células Tumorais Cultivadas
13.
Eur J Hum Genet ; 5(3): 171-4, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9272742

RESUMO

Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) is an autosomal dominant condition consisting of congenital dysplasia of the eyelids with a reduced horizontal diameter of the palpebral fissures, droopy eyelids and epicanthus inversus. Two clinical entities have been described: type I and type II. The former is distinguished by female infertility, whereas the latter presents without other symptoms. Both type I and type II were recently mapped on the long arm of chromosome 3 (3q22-q23), suggesting a common gene may be affected. The centromeric and the telomeric limits of this region are well defined between loci D3S1316 and D3S1615, which reside approximately 5 cM apart. Here, we present the construction of a YAC contig spanning the entire BPES locus using 17 polymorphic markers, 2 STS and 28 ESTs. This region of approximately 5 Mb was covered by 31 YACs, and was supported by detailed FISH analysis. In addition, we have precisely mapped the propionyl-CoA carboxylase beta polypeptide (PCCB), the gene mutated in propionic acidemia, within this contig. Apart from providing a framework for the identification of the BPES gene, this contig will also be useful for the future identification of defects and genes mapped to this region, and for developing template resources for genomic sequencing.


Assuntos
Erros Inatos do Metabolismo dos Aminoácidos/genética , Blefarofimose/genética , Blefaroptose/genética , Mapeamento Cromossômico , Cromossomos Artificiais de Levedura/genética , Cromossomos Humanos Par 3/ultraestrutura , Propionatos/sangue , Carboxiliases/genética , Primers do DNA , Feminino , Técnica Indireta de Fluorescência para Anticorpo , Marcadores Genéticos , Humanos , Hibridização in Situ Fluorescente , Infertilidade Feminina/genética , Metilmalonil-CoA Descarboxilase , Reação em Cadeia da Polimerase , Polimorfismo Genético , Sequências Repetitivas de Ácido Nucleico , Sitios de Sequências Rotuladas , Síndrome
14.
Bone Marrow Transplant ; 17(4): 625-32, 1996 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-8722366

RESUMO

In one case out of four, allogeneic BMT concerns a male recipient and a female donor. The monitoring of sex-matched BMT can be carried out by PCR amplification on Y-specific chromosome sequences (YCS), whatever the hematological disease. Twelve patients with sex-mismatched non-T-depleted BMT were first studied through a qualitative PCR, which gave semi-quantitative results. When the qualitative PCR revealed YCS, a competitive amplification was performed in order to estimate the YCS amount in the patient blood sample. For the purpose of the study, we classified the patients in two categories according to the results obtained 9 months after BMT. For 10 patients, we did not detect any YCS amplification after this time. These patients were in complete cytogenetic and clinical remission. For the remaining two patients, we always found male DNA in their blood samples. These patients were in cytogenetic remission but relapsed and died 21 and 25 months after BMT. Our results suggest that the persistence of male cells in peripheral blood, even at the low rate of 1% or 0.1%, 1 year after sex-mismatched BMT, is a bad prognosis.


Assuntos
Transplante de Medula Óssea/patologia , Leucemia/patologia , Recidiva Local de Neoplasia/epidemiologia , Reação em Cadeia da Polimerase , Cromossomo Y , Sequência de Bases , Transplante de Medula Óssea/estatística & dados numéricos , Sobrevivência Celular , Quimera , DNA/sangue , Sondas de DNA , Feminino , Seguimentos , Marcadores Genéticos , Sobrevivência de Enxerto , Doença Enxerto-Hospedeiro , Humanos , Leucemia/mortalidade , Leucemia/terapia , Masculino , Neoplasia Residual , Prognóstico , Indução de Remissão , Transplante Homólogo , Falha de Tratamento , Cromossomo Y/genética
16.
Bone Marrow Transplant ; 13(2): 217-9, 1994 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8205094

RESUMO

A 51-year-old man with previously treated CLL received an allogeneic sex mismatched BMT after total body irradiation and high dose chemotherapy. Residual disease was studied at phenotypic and molecular levels including Y chromosome DNA amplification by PCR assay. The patient was clinically disease-free 20 months after BMT with disappearance of the leukemic clone assessed by the most sensitive methods of detection. Long-term follow-up is necessary to ascertain the relevance of Y DNA amplification in predicting outcome in this patient.


Assuntos
Transplante de Medula Óssea , Leucemia Linfocítica Crônica de Células B/genética , Leucemia Linfocítica Crônica de Células B/terapia , Antineoplásicos/uso terapêutico , Sequência de Bases , Southern Blotting , DNA de Neoplasias/genética , Amplificação de Genes , Humanos , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Fenótipo , Reação em Cadeia da Polimerase , Indução de Remissão , Irradiação Corporal Total , Cromossomo Y
19.
Hum Genet ; 88(5): 508-12, 1992 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-1372586

RESUMO

Since the isolation of the cystic fibrosis transmembrane conductance regulator gene (CFTR) and the characterization of the main mutation (delta F508) in 1989, a large number of rare mutations has been found. Full screening of the CFTR gene is difficult because it is split into 27 exons covering 250 kb of genomic DNA. This gene is essentially expressed in the lung and intestinal tract, neither of which are easily accessible for routine investigations. The recent description of a faint transcription of highly tissue-specific genes in any cell, a phenomenon known as illegitimate transcription, would facilitate the research of mutations and the characterization of truncated m-RNA caused by splicing mutations. Using the polymerase chain reaction on cDNA (cDNA-PCR), we detected transcripts of the CFTR gene in lymphocytes and lymphoblast cells at a very low level (about 300 times less than in lung or intestine). This strategy allowed us to obtain a sufficient amount of cDNA-PCR product compatible with further molecular analyses. We have, therefore, analyzed a cDNA fragment overlapping exons 10 and 11 by polyacrylamide gel electrophoresis and direct sequencing, and detected the delta F508 mutation at this level. Our protocol can be generalized to the investigation of the total 4.5-kb CFTR coding sequence.


Assuntos
Fibrose Cística/genética , Linfócitos/fisiologia , Proteínas de Membrana/genética , Transcrição Gênica , Animais , Sequência de Bases , Regulador de Condutância Transmembrana em Fibrose Cística , DNA/genética , DNA/isolamento & purificação , Éxons , Humanos , Fígado/enzimologia , Dados de Sequência Molecular , Oligodesoxirribonucleotídeos , Especificidade de Órgãos , Reação em Cadeia da Polimerase/métodos , Piruvato Quinase/genética , RNA Mensageiro/genética , RNA Mensageiro/isolamento & purificação , Ratos , Mapeamento por Restrição
20.
Ann Genet ; 34(1): 5-7, 1991.
Artigo em Inglês | MEDLINE | ID: mdl-1952795

RESUMO

The frequencies of the delta F 508 mutation and haplotypes linked to the cystic fibrosis (CF) gene and detected with DNA probes XV-2C and KM-19 have been studied in the population of Reunion Island, a French province located in the Indian Ocean. The deletion was present in 41.3% of CF chromosomes, whereas this proportion is about 70% in the French population. The delta F 508 mutation was associated with the haplotype B defined by the DNA markers XV-2C (allele 1) and KM-19 (allele 2) in 76.4% of CF chromosomes, while this proportion is over 90% in the French population. Founder effect, genetic drift and admixture can explain these differences.


Assuntos
Fibrose Cística/epidemiologia , Criança , Deleção Cromossômica , Fibrose Cística/etnologia , Fibrose Cística/genética , Sondas de DNA , França/etnologia , Frequência do Gene , Marcadores Genéticos , Haplótipos , Humanos , Incidência , Ilhas do Oceano Índico/epidemiologia , Desequilíbrio de Ligação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA